Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 8, 2010, Pages 839-845

  Cossec, Jack Christophe ^a   Marquer, Catherine ^a   Panchal, Mai ^a   Lazar, Adina N ^a   Duyckaerts, Charles ^a   Potier, Marie Claude ^a  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

Alzheimer's disease; Cholesterol; Down syndrome; Endosome; Methyl beta cyclodextrine; Rab5

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; CP 113818; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BIOCHEMISTRY; CELL MEMBRANE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOLOGY; DISEASE MODEL; DOWN SYNDROME; DRUG MECHANISM; ENDOSOME; GENETIC ASSOCIATION; HUMAN; METABOLITE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; BRAIN CHEMISTRY; CHOLESTEROL; ENDOSOMES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LIPID METABOLISM;

ANIMALIA;

EID: 77953273656     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.03.010     Document Type: Review

References (72)

1. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 4 (2003) 345-351
2. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 1 (2004) 7-10
3. Ledesma M.D., and Dotti C.G. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. FEBS Lett. 580 23 (2006) 5525-5532
4. Grimm M.O., Grimm H.S., and Hartmann T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med. 13 8 (2007) 337-344
5. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10 5 (2009) 333-344
6. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 5123 (1993) 921-923
7. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41 10 (2009) 1088-1093
8. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., and Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41 10 (2009) 1094-1099
9. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., and Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 58 5 (2008) 681-693
10. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschape J.A., De Strooper B., Muller U., Shen J., and Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7 11 (2005) 1118-1123
11. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., Herz J., Muglia L., and Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56 1 (2007) 66-78
12. Hamanaka H., Katoh-Fukui Y., Suzuki K., Kobayashi M., Suzuki R., Motegi Y., Nakahara Y., Takeshita A., Kawai M., Ishiguro K., Yokoyama M., and Fujita S.C. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet. 9 3 (2000) 353-361
13. Mann K.M., Thorngate F.E., Katoh-Fukui Y., Hamanaka H., Williams D.L., Fujita S., and Lamb B.T. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum. Mol. Genet. 13 17 (2004) 1959-1968
14. Hayashi H., Igbavboa U., Hamanaka H., Kobayashi M., Fujita S.C., Wood W.G., and Yanagisawa K. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. NeuroReport 13 4 (2002) 383-386
15. Beel A.J., Mobley C.K., Kim H.J., Tian F., Hadziselimovic A., Jap B., Prestegard J.H., and Sanders C.R. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. Biochemistry 47 36 (2008) 9428-9446
16. Carter C.J. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50 1 (2007) 12-38
17. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39 1 (2007) 17-23
18. Wollmer M.A., Streffer J.R., Tsolaki M., Grimaldi L.M., Lutjohann D., Thal D., von Bergmann K., Nitsch R.M., Hock C., and Papassotiropoulos A. Genetic association of acyl-coenzyme A:cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol. Psychiatry 8 6 (2003) 635-638
19. Rudolf M., and Curcio C.A. Esterified cholesterol is highly localized to Bruch's membrane, as revealed by lipid histochemistry in wholemounts of human choroid. J. Histochem. Cytochem. 57 8 (2009) 731-739
20. Ohm T.G., Treiber-Held S., Distl R., Glockner F., Schonheit B., Tamanai M., and Meske V. Cholesterol and tau protein-findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 36 Suppl 2 (2003) S120-6
21. Burns M.P., Noble W.J., Olm V., Gaynor K., Casey E., LaFrancois J., Wang L., and Duff K. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res. Mol. Brain Res. 110 1 (2003) 119-125
22. Mori T., Paris D., Town T., Rojiani A.M., Sparks D.L., Delledonne A., Crawford F., Abdullah L.I., Humphrey J.A., Dickson D.W., and Mullan M.J. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60 8 (2001) 778-785
23. Lebouvier T., Perruchini C., Panchal M., Potier M.C., and Duyckaerts C. Cholesterol in the senile plaque: often mentioned, never seen. Acta Neuropathol. 117 1 (2009) 31-34
24. Garvik O., Benediktson P., Simonsen A.C., Ipsen J.H., and Wustner D. The fluorescent cholesterol analog dehydroergosterol induces liquid-ordered domains in model membranes. Chem. Phys. Lipids 159 2 (2009) 114-118
25. Marks D.L., Bittman R., and Pagano R.E. Use of Bodipy-labeled sphingolipid and cholesterol analogs to examine membrane microdomains in cells. Histochem. Cell Biol. 130 5 (2008) 819-832
26. Kirsch C., Eckert G.P., Koudinov A.R., and Muller W.E. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 36 Suppl 2 (2003) S113-9
27. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., and Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 29 3 (2008) 422-437
28. Reid P.C., Sakashita N., Sugii S., Ohno-Iwashita Y., Shimada Y., Hickey W.F., and Chang T.Y. A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann-Pick type C1 mouse brain. J. Lipid Res. 45 3 (2004) 582-591
29. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 7 (2004) 2070-2075
30. Heverin M., Bogdanovic N., Lutjohann D., Bayer T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B., and Bjorkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45 1 (2004) 186-193
31. Hascalovici J.R., Vaya J., Khatib S., Holcroft C.A., Zukor H., Song W., Arvanitakis Z., Bennett D.A., and Schipper H.M. Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1. J. Neurochem. 110 4 (2009) 1241-1253
32. Panchal M., Loeper J., Cossec J.C., Perruchini C., Lazar A., Pompon D., and Duyckaerts C. Enrichment of cholesterol in microdissected Alzheimer disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 51 3 (2009) 598-605
33. Rufenacht P., Guntert A., Bohrmann B., Ducret A., and Dobeli H. Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J. Mass Spectrom. 40 2 (2005) 193-201
34. Brunelle A., and Laprevote O. Lipid imaging with cluster time-of-flight secondary ion mass spectrometry. Anal. Bioanal. Chem. 393 1 (2009) 31-35
35. Tahallah N., Brunelle A., De La Porte S., and Laprevote O. Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging. J. Lipid Res. 49 2 (2008) 438-454
36. Debois D., Bralet M.P., Le Naour F., Brunelle A., and Laprevote O. In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF-SIMS imaging. Anal. Chem. 81 8 (2009) 2823-2831
37. Piehowski P.D., Carado A.J., Kurczy M.E., Ostrowski S.G., Heien M.L., Winograd N., and Ewing A.G. MS/MS methodology to improve subcellular mapping of cholesterol using TOF-SIMS. Anal. Chem. 80 22 (2008) 8662-8667
38. Wakelam M.J., Pettitt T.R., and Postle A.D. Lipidomic analysis of signaling pathways. Methods Enzymol. 432 (2007) 233-246
39. Zehethofer N., and Pinto D.M. Recent developments in tandem mass spectrometry for lipidomic analysis. Anal. Chim. Acta 627 1 (2008) 62-70
40. Dreissig I., Machill S., Salzer R., and Krafft C. Quantification of brain lipids by FTIR spectroscopy and partial least squares regression. Spectrochim. Acta A Mol. Biomol. Spectrosc. 71 5 (2009) 2069-2075
41. Hutter-Paier B., Huttunen H.J., Puglielli L., Eckman C.B., Kim D.Y., Hofmeister A., Moir R.D., Domnitz S.B., Frosch M.P., Windisch M., and Kovacs D.M. The ACAT inhibitor CP-113, 818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44 2 (2004) 227-238
42. Bryleva E.Y., Rogers M.A., Chang C.C., Buen F., Harris B.T., Rousselet E., Seidah N.G., Oddo S., Laferla F.M., Spencer T.A., Hickey W.F., and Chang T.Y. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. U. S. A. 107 7 (2010) 3081-3086
43. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., and Kovacs D.M. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3 10 (2001) 905-912
44. Huttunen H.J., Greco C., and Kovacs D.M. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett. 581 8 (2007) 1688-1692
45. Huttunen H.J., Puglielli L., Ellis B.C., MacKenzie Ingano L.A., and Kovacs D.M. Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J. Mol. Neurosci. 37 1 (2009) 6-15
46. Corrigan F.M., Horrobin D.F., Skinner E.R., Besson J.A., and Cooper M.B. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int. J. Biochem. Cell Biol. 30 2 (1998) 197-207
47. Montine T.J., Montine K.S., and Swift L.L. Central nervous system lipoproteins in Alzheimer's disease. Am. J. Pathol. 151 6 (1997) 1571-1575
48. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 1 (2003) 113-123
49. Pralle A., Keller P., Florin E.L., Simons K., and Horber J.K. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J. Cell Biol. 148 5 (2000) 997-1008
50. Bouillot C., Prochiantz A., Rougon G., and Allinquant B. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J. Biol. Chem. 271 13 (1996) 7640-7644
51. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 11 (1998) 6460-6464
52. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98 10 (2001) 5815-5820
53. Schrader-Fischer G., and Paganetti P.A. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 716 1-2 (1996) 91-100
54. Carey R.M., Balcz B.A., Lopez-Coviella I., and Slack B.E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 6 (2005) 30
55. von Arnim C.A., von Einem B., Weber P., Wagner M., Schwanzar D., Spoelgen R., Strauss W.L., and Schneckenburger H. Impact of cholesterol level upon APP and BACE proximity and APP cleavage. Biochem. Biophys. Res. Commun. 370 2 (2008) 207-212
56. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 9 (2004) 1624-1628
57. Wood W.G., Schroeder F., Igbavboa U., Avdulov N.A., and Chochina S.V. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23 5 (2002) 685-694
58. Taylor D.R., and Hooper N.M. Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin. Cell Dev. Biol. 18 5 (2007) 638-648
59. Cataldo A.M., Barnett J.L., Pieroni C., and Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17 16 (1997) 6142-6151
60. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., and Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157 1 (2000) 277-286
61. Cataldo A.M., Mathews P.M., Boiteau A.B., Hassinger L.C., Peterhoff C.M., Jiang Y., Mullaney K., Neve R.L., Gruenberg J., and Nixon R.A. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 173 2 (2008) 370-384
62. Cataldo A., Rebeck G.W., Ghetri B., Hulette C., Lippa C., Van Broeckhoven C., van Duijn C., Cras P., Bogdanovic N., Bird T., Peterhoff C., and Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann. Neurol. 50 5 (2001) 661-665
63. Laifenfeld D., Patzek L.J., McPhie D.L., Chen Y., Levites Y., Cataldo A.M., and Neve R.L. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J. Neurosci. 27 27 (2007) 7141-7153
64. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., Carlson E.J., Staufenbiel M., and Nixon R.A. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 23 17 (2003) 6788-6792
65. Jiang Y., Mullaney K.A., Peterhoff C.M., Che S., Schmidt S.D., Boyer-Boiteau A., Ginsberg S.D., Cataldo A.M., Mathews P.M., and Nixon R.A. Alzheimer's-related endosome dysfunction in Down syndrome is A{beta}-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. (2009)
66. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., and Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 1 (2006) 24-26
67. Grbovic O.M., Mathews P.M., Jiang Y., Schmidt S.D., Dinakar R., Summers-Terio N.B., Ceresa B.P., Nixon R.A., and Cataldo A.M. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J. Biol. Chem. 278 33 (2003) 31261-31268
68. Bucci C., Parton R.G., Mather I.H., Stunnenberg H., Simons K., Hoflack B., and Zerial M. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 70 5 (1992) 715-728
69. Roberts R.L., Barbieri M.A., Pryse K.M., Chua M., Morisaki J.H., and Stahl P.D. Endosome fusion in living cells overexpressing GFP-rab5. J. Cell Sci. 112 Pt 21 (1999) 3667-3675
70. Hudry E., Van Dam D., Kulik W., De Deyn P.P., Stet F.S., Ahouansou O., Benraiss A., Delacourte A., Bougneres P., Aubourg P., and Cartier N. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18 1 (2010) 44-53
71. Xu S., Benoff B., Liou H.L., Lobel P., and Stock A.M. Structural basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann-Pick type C2 disease. J. Biol. Chem. 282 32 (2007) 23525-23531
72. Kwon H.J., Abi-Mosleh L., Wang M.L., Deisenhofer J., Goldstein J.L., Brown M.S., and Infante R.E. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137 7 (2009) 1213-1224